MCM2 and familial pancreatic carcinoma: Reduced levels of Mcm2 serine 53 phosphorylation was observed at all PHA-767491 drug concentrations in both pancreatic cancer cell lines and IMR-90 fibroblasts 96 hours following treatment with the inhibitor.